Form 4: Plus Therapeutics Director Acquires Stock Options

An van Es-Johansson, a director of Plus Therapeutics, Inc., acquired stock options on February 18, 2025.

Summary

• An van Es-Johansson, a director at Plus Therapeutics, Inc. (PSTV), filed a Form 4 on February 20, 2025.
• The filing reports a transaction that occurred on February 18, 2025, where van Es-Johansson acquired 40,122 stock options with an exercise price of $1.18.
• These options vest monthly over 12 months from the grant date, with full vesting occurring at the Issuer's 2026 Annual Stockholder Meeting, contingent on continued service.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance.

Future Outlook

The acquired stock options vest over the next 12 months, contingent on the director's continued service, aligning the director's interests with the company's performance through the 2026 Annual Stockholder Meeting.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers. This allows investors to monitor insider activity, which can provide insights into management's perspective on the company's value and prospects.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, Stock Options, Director, PSTV, Plus Therapeutics, Beneficial Ownership